Ou et al., 2022 - Google Patents
Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificityOu et al., 2022
View PDF- Document ID
- 2591071682834309251
- Author
- Ou Y
- Liu M
- Zhan K
- Wu W
- Huang J
- Sun H
- Zheng H
- Yu X
- Gong H
- Han Z
- Chen A
- Liao Y
- Lin Y
- Liu G
- Liu Q
- Ma R
- Mei Y
- Tang X
- Weng Z
- Wu J
- Ye Y
- Zhang T
- Chen J
- Chen L
- Ding Q
- Fan H
- Hu J
- Huang J
- Huang L
- Li Q
- Li S
- Liu M
- Shi J
- Tan X
- Wang X
- Xiang R
- Yan Q
- Zhang J
- Zheng W
- Zhong S
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
The clinical success of T-cell receptor (TCR)-based immunotherapy depends on the efficacy and specificity of TCRs. Naturally occurring TCRs have limited anti-tumor potency due to their low affinity for tumor antigens. Affinity enhancement is a promising strategy to generate …
- 102100001891 CTAG1A 0 title description 72
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shafer et al. | Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects | |
| JP7730765B2 (en) | MAGE-A4 T-CELL RECEPTOR AND METHODS OF USE THEREOF | |
| TWI840351B (en) | T cell receptors and engineered cells expressing same | |
| EP3177314B1 (en) | T cell immunotherapy specific for wt-1 | |
| US12358968B2 (en) | Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer | |
| US11730796B2 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| EP3995142A2 (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| AU2018360599A1 (en) | Process for generating therapeutic compositions of engineered cells | |
| JP2023534808A (en) | Receptors that provide targeted co-stimulation for adoptive cell therapy | |
| JP2019512242A (en) | Transfected T cells and T cell receptors for use in immunotherapy for cancer | |
| US20230178239A1 (en) | Methods of identifying features associated with clinical response and uses thereof | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| JP2023133505A (en) | Cyclin A1-specific T cell receptor and its uses | |
| US20230192886A1 (en) | Adoptive cell therapy combination treatment and compositions thereof | |
| EP3209679A1 (en) | T cell-based immunotherapeutics | |
| Ou et al. | Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity | |
| EP4253410A1 (en) | Ras mutant epitope peptide and t cell receptor recognizing ras mutant | |
| US20240058447A1 (en) | Use of fusion constructs for il-2 independent t cell therapy | |
| Zhou et al. | Alanine mutagenesis in the complementarity determining region 3 of the MTB and HIV-1 peptide-bispecific T cell receptor beta chain affects ligand recognition | |
| CN121127488A (en) | T cell receptor and application thereof | |
| US20240122980A1 (en) | Use of tim-3 cytoplasmic tail in chimeric antigen receptors | |
| HK40074429A (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| WO2024148223A1 (en) | Epitope engineering of cd38 cell-surface receptors | |
| Dow et al. | 7 The Development of Adoptive T-Cell Immunotherapies for Cancer | |
| CN120303292A (en) | pMHC-binding heterodimeric receptor with improved discrimination for low-affinity and high-affinity pMHC and without binding to CD3 |